Compare Genuine Parts Company (GPC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs State Street SPDR S&P Biotech ETF — how do they compare? Genuine Parts Company trades at $133.71 (market cap $18.62B), while State Street SPDR S&P Biotech ETF trades at $159.76. The key difference: Genuine Parts Company pays a 3.15% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Genuine Parts Company nearer its low. Which is the better fit depends on your goals.
| GPC | XBI | |
|---|---|---|
Market Cap | $18.62B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $149.26 | $164.28 |
52-Week Low | $92.47 | $86.92 |
Enterprise Value | $24.72B | — |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $134.54, down 0.8% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings with EPS of $2.15 beating estimates of $2.08, while revenue grew 6% year-over-year to $6.5 billion. However, net income margin remains thin at 0.13% for 2025, though the P/S ratio of 0.75 suggests reasonable valuation relative to sales.
The stock offers a dividend yield supported by 70 years of increases, with analyst consensus target at $148.67 suggesting 10.5% upside. Key risks include compressed profit margins, rising debt levels, and sensitivity to automotive industry cycles. Institutional ownership shows mixed signals with some funds increasing positions while others trimmed holdings in Q1 2026.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
